Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | AKT2 | P31751 | 2/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002860 | 0.80 | BCL2 (0.64) | BCL2NPSR1POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL28708715 | 0.80 | BCL2 (0.61) | BCL2NPSR1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1984793 | 0.79 | BCL2 (0.41) | BCL2NPSR1POLBSMN1; SMN2MAPK1 | |
| SCHEMBL2006125 | 0.78 | CHRM4 (0.56) | BCL2SMN1; SMN2MAPK1KIF11LMNA | |
| SCHEMBL9196329 | 0.78 | NPSR1 (0.53) | BCL2NPSR1POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL23880652 | 0.78 | CYP2D6 (0.44) | BCL2NPSR1POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL8313158 | 0.78 | BCL2 (0.40) | BCL2NPSR1POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL6048472 | 0.77 | SIGMAR1 (0.58) | BCL2SMN1; SMN2MAPK1LMNACHRM3 | |
| SCHEMBL7462429 | 0.76 | CCR1 (0.44) | BCL2L3MBTL1MEN1KMT2ATSHR | |
| SCHEMBL7606639 | 0.75 | KIF11 (0.46) | BCL2NPSR1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960526-B2 | Colorimetric-oxycarbonyl protecting groups for use in organic syntheses | BERRY AND ASSOCIATES, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960526-B2 | Colorimetric-oxycarbonyl protecting groups for use in organic syntheses | BERRY AND ASSOCIATES, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960526-B2 | Colorimetric-oxycarbonyl protecting groups for use in organic syntheses | BERRY AND ASSOCIATES, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| WO-2010114762-A1 | COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES | BERRY AND ASSOCIATES, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249393-A1 | COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES | BERRY AND ASSOCIATES, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249393-A1 | COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES | BERRY AND ASSOCIATES, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249393-A1 | COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES | BERRY AND ASSOCIATES, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249393-A1 | COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES | RNGTT, OGA, HCCS | BCL2 2618/4885NPSR1 2994/4885POLB 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.